David MacDonald
Direttore Tecnico/Scientifico/R&S presso XORTX THERAPEUTICS INC.
Profilo
David MacDonald is currently the Chief Technology Officer at XORTX Therapeutics, Inc. He previously held positions as President & Chief Executive Officer at Active Pass Pharmaceuticals, Inc., Chief Technology Officer & Vice President at MSI Methylation Sciences, Inc., Section Leader at Hemosol Corp., Staff Researcher at Syntex, Inc., and General Manager at Biovail Contract Research Division.
He also served as the Chief Technology Officer at Immunoflex Therapeutics, Inc. from 2020 to 2021.
Dr. MacDonald obtained a doctorate degree from the University of Alberta.
Posizioni attive di David MacDonald
| Società | Posizione | Inizio |
|---|---|---|
| XORTX THERAPEUTICS INC. | Direttore Tecnico/Scientifico/R&S | 20/01/2022 |
Precedenti posizioni note di David MacDonald
| Società | Posizione | Fine |
|---|---|---|
| Immunoflex Therapeutics, Inc. | Direttore Tecnico/Scientifico/R&S | 01/01/2021 |
| Biovail Contract Research Division | Corporate Officer/Principal | - |
Hemosol Corp. /Old/
 Hemosol Corp. /Old/ Pharmaceuticals: MajorHealth Technology Hemosol Inc. is an integrated biopharmaceutical company focused on the development of a portfolio of products based on human hemoglobin. | Corporate Officer/Principal | - |
| Syntex, Inc. | Corporate Officer/Principal | - |
MSI Methylation Sciences, Inc.
 MSI Methylation Sciences, Inc. Pharmaceuticals: MajorHealth Technology MSI Methylation Sciences, Inc. engages in drug development through compound leverage. It focuses on developing pharmaceuticals based on molecules with proven efficacy that are under exploited in pharmaceutical markets. The firm offers s-adenosyl methionine, is a prescription drug used as a dietary supplement. The company was founded by Barry J. Guld and Nancy Harrison in 2006 and is headquartered in Burnaby, Canada. | Presidente | - |
Formazione di David MacDonald
| University of Alberta | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| XORTX THERAPEUTICS INC. | Health Technology |
| Aziende private | 6 |
|---|---|
MSI Methylation Sciences, Inc.
MSI Methylation Sciences, Inc. Pharmaceuticals: MajorHealth Technology MSI Methylation Sciences, Inc. engages in drug development through compound leverage. It focuses on developing pharmaceuticals based on molecules with proven efficacy that are under exploited in pharmaceutical markets. The firm offers s-adenosyl methionine, is a prescription drug used as a dietary supplement. The company was founded by Barry J. Guld and Nancy Harrison in 2006 and is headquartered in Burnaby, Canada. | Health Technology |
Hemosol Corp. /Old/
Hemosol Corp. /Old/ Pharmaceuticals: MajorHealth Technology Hemosol Inc. is an integrated biopharmaceutical company focused on the development of a portfolio of products based on human hemoglobin. | Health Technology |
Active Pass Pharmaceuticals, Inc.
 Active Pass Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Active Pass Pharmaceuticals, Inc. develops drugs for infectious diseases. It engages in the development of drugs that inhibit ABC transporters. The firm also provides portfolio of therapeutic programs, including age-related macular degeneration, travelers' diarrhea, and lipid disorders. The company was founded by Peter B Reiner in 1998 and is headquartered in Vancouver, Canada. | Health Technology |
| Syntex, Inc. | Miscellaneous |
| Biovail Contract Research Division | Commercial Services |
| Immunoflex Therapeutics, Inc. |
- Borsa valori
- Insiders
- David MacDonald
